These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

804 related articles for article (PubMed ID: 24144967)

  • 1. Management of endocrine disease: GH excess: diagnosis and medical therapy.
    Andersen M
    Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Optimization of the medical treatment for acromegaly].
    Díez JJ; Iglesias P
    Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
    Feelders RA; Hofland LJ; van Aken MO; Neggers SJ; Lamberts SW; de Herder WW; van der Lely AJ
    Drugs; 2009 Nov; 69(16):2207-26. PubMed ID: 19852525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K; Lamberts SW
    Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acromegaly.
    Scacchi M; Cavagnini F
    Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists.
    Howlett TA; Willis D; Walker G; Wass JA; Trainer PJ;
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):689-99. PubMed ID: 23574573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
    Colao A; Auriemma RS; Pivonello R
    Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current pharmacotherapy for acromegaly: a review.
    Biermasz NR; Romijn JA; Pereira AM; Roelfsema F
    Expert Opin Pharmacother; 2005 Nov; 6(14):2393-405. PubMed ID: 16259571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of medical treatment in patients with acromegaly in clinical practice.
    Lee SY; Kim JH; Lee JH; Kim YH; Cha HJ; Kim SW; Paek SH; Shin CS
    Endocr J; 2018 Jan; 65(1):33-41. PubMed ID: 28931779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New perspectives in the medical treatment of acromegaly.
    Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G
    J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
    Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
    Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors.
    Shimon I; Jallad RS; Fleseriu M; Yedinak CG; Greenman Y; Bronstein MD
    Eur J Endocrinol; 2015 Jun; 172(6):707-13. PubMed ID: 25792375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
    Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
    Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of pituitary adenomas].
    Mezosi E; Nemes O
    Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future medical treatments for patients with acromegaly.
    Maffezzoni F; Formenti AM; Mazziotti G; Frara S; Giustina A
    Expert Opin Pharmacother; 2016 Aug; 17(12):1631-42. PubMed ID: 27352098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
    Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Outcome of somatostatin analogue treatment in acromegaly].
    Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
    Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.